Tags

Type your tag names separated by a space and hit enter

Valdecoxib is as efficacious as diclofenac in the treatment of acute low back pain.
Clin J Pain. 2007 Mar-Apr; 23(3):244-50.CJ

Abstract

OBJECTIVE

To compare the efficacy of valdecoxib 40 mg q.d. (with a second dose on day 1) with diclofenac 75 mg b.i.d. in the treatment of acute low back pain.

METHODS

This was a multicenter, randomized, double-blind study. Patients with acute low back pain, class 1a or 2a (Quebec Task Force), with a visual analog scale score >/=50 mm (on a 100-mm scale) and moderate to severe pain on a categorical scale, were randomized to valdecoxib 40 mg q.d. (with a second dose on day 1) or diclofenac 75 mg b.i.d. for 7 days (170 patients per group). The primary efficacy end point was change in pain intensity (visual analog scale, mm) from baseline to day 3 for the per-protocol population.

RESULTS

Least squares mean reductions in pain intensity from baseline to day 3 were similar for valdecoxib (-42.02 mm) and diclofenac (-41.43 mm). Valdecoxib was comparable to diclofenac as the lower limit of the 95% confidence interval of the estimated difference (0.59 mm; 95% confidence interval, -3.40 to 4.59 mm) was within the prespecified noninferiority margin of -10 mm. The overall incidence of adverse events was similar for valdecoxib (28%) and diclofenac (26%). No statistically different moderate or severe upper gastrointestinal adverse events were reported, although they were numerically greater for diclofenac (8) than for valdecoxib (3).

DISCUSSION

Valdecoxib 40 mg q.d. (with a second dose on day 1) provides effective relief for acute low back pain, and was at least as efficacious as diclofenac 75 mg b.i.d., with a nonsignificant but numerically lower incidence of gastrointestinal adverse events.

Authors+Show Affiliations

Department of Internal Medicine, Division of Rheumatology, Hospital Geral de Goiânia, Goiânia, GO, Brazil.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17314584

Citation

Ximenes, Antonio, et al. "Valdecoxib Is as Efficacious as Diclofenac in the Treatment of Acute Low Back Pain." The Clinical Journal of Pain, vol. 23, no. 3, 2007, pp. 244-50.
Ximenes A, Robles M, Sands G, et al. Valdecoxib is as efficacious as diclofenac in the treatment of acute low back pain. Clin J Pain. 2007;23(3):244-50.
Ximenes, A., Robles, M., Sands, G., & Vinueza, R. (2007). Valdecoxib is as efficacious as diclofenac in the treatment of acute low back pain. The Clinical Journal of Pain, 23(3), 244-50.
Ximenes A, et al. Valdecoxib Is as Efficacious as Diclofenac in the Treatment of Acute Low Back Pain. Clin J Pain. 2007 Mar-Apr;23(3):244-50. PubMed PMID: 17314584.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Valdecoxib is as efficacious as diclofenac in the treatment of acute low back pain. AU - Ximenes,Antonio, AU - Robles,Manuel, AU - Sands,George, AU - Vinueza,Raul, PY - 2007/2/23/pubmed PY - 2007/4/25/medline PY - 2007/2/23/entrez SP - 244 EP - 50 JF - The Clinical journal of pain JO - Clin J Pain VL - 23 IS - 3 N2 - OBJECTIVE: To compare the efficacy of valdecoxib 40 mg q.d. (with a second dose on day 1) with diclofenac 75 mg b.i.d. in the treatment of acute low back pain. METHODS: This was a multicenter, randomized, double-blind study. Patients with acute low back pain, class 1a or 2a (Quebec Task Force), with a visual analog scale score >/=50 mm (on a 100-mm scale) and moderate to severe pain on a categorical scale, were randomized to valdecoxib 40 mg q.d. (with a second dose on day 1) or diclofenac 75 mg b.i.d. for 7 days (170 patients per group). The primary efficacy end point was change in pain intensity (visual analog scale, mm) from baseline to day 3 for the per-protocol population. RESULTS: Least squares mean reductions in pain intensity from baseline to day 3 were similar for valdecoxib (-42.02 mm) and diclofenac (-41.43 mm). Valdecoxib was comparable to diclofenac as the lower limit of the 95% confidence interval of the estimated difference (0.59 mm; 95% confidence interval, -3.40 to 4.59 mm) was within the prespecified noninferiority margin of -10 mm. The overall incidence of adverse events was similar for valdecoxib (28%) and diclofenac (26%). No statistically different moderate or severe upper gastrointestinal adverse events were reported, although they were numerically greater for diclofenac (8) than for valdecoxib (3). DISCUSSION: Valdecoxib 40 mg q.d. (with a second dose on day 1) provides effective relief for acute low back pain, and was at least as efficacious as diclofenac 75 mg b.i.d., with a nonsignificant but numerically lower incidence of gastrointestinal adverse events. SN - 0749-8047 UR - https://www.unboundmedicine.com/medline/citation/17314584/Valdecoxib_is_as_efficacious_as_diclofenac_in_the_treatment_of_acute_low_back_pain_ L2 - https://doi.org/10.1097/AJP.0b013e31802f67c6 DB - PRIME DP - Unbound Medicine ER -